Vaxart Company Insiders
| VXRT Stock | USD 0.36 0.02 5.26% |
Vaxart employs about 105 people. The company is managed by 16 executives with a total tenure of roughly 14 years, averaging almost 0.0 years of service per executive, having 6.56 employees per reported executive. Breaking down Vaxart's management performance can provide insight into the firm performance.
Vaxart Management Team Effectiveness
The company has return on total asset (ROA) of (0.1625) % which means that it has lost $0.1625 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0652) %, meaning that it created substantial loss on money invested by shareholders. Vaxart's management efficiency ratios could be used to measure how well Vaxart manages its routine affairs as well as how well it operates its assets and liabilities.Vaxart Workforce Comparison
Vaxart Inc is rated first in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 84,808. Vaxart adds roughly 105 in number of employees claiming only tiny portion of equities under Health Care industry.
The company has Profit Margin (PM) of (0.34) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.11) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.11. Vaxart Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vaxart insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vaxart's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Vaxart insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Heron Elaine J six days ago Acquisition by Heron Elaine J of 23217 shares of Vaxart at 0.393 subject to Rule 16b-3 | ||
Phillip Lee over three months ago Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3 | ||
Phillip Lee over three months ago Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3 | ||
Phillip Lee over three months ago Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3 | ||
Phillip Lee over three months ago Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3 | ||
Phillip Lee over three months ago Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3 | ||
Phillip Lee over three months ago Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3 | ||
Phillip Lee over three months ago Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3 |
Vaxart Notable Stakeholders
A Vaxart stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Vaxart often face trade-offs trying to please all of them. Vaxart's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Vaxart's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Steven Lo | CEO President | Profile | |
| Phillip Lee | Principal CFO | Profile | |
| Jeroen MBA | Principal CFO | Profile | |
| Michael Finney | Interim Director | Profile | |
| Sarah Khan | VP Resources | Profile | |
| Rajesh Kapoor | Senior Quality | Profile | |
| Shaily Garg | Senior Management | Profile | |
| Brant Biehn | Sr Operations | Profile | |
| Cezar MBA | Pres CEO | Profile | |
| James MD | Chief Officer | Profile | |
| Fuad Ahmad | Interim Officer | Profile | |
| CPA MBA | Consultant | Profile | |
| Dr Stapleton | Chief Officer | Profile | |
| Sean Tucker | Chief Scientific Officer | Profile | |
| Laurie Hastings | Senior Resources | Profile | |
| Edward Berg | Senior Counsel | Profile |
About Vaxart Management Performance
The success or failure of an entity such as Vaxart Inc often depends on how effective the management is. Vaxart management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Vaxart management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Vaxart management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company is headquartered in South San Francisco, California. Vaxart operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people.
Please note, the imprecision that can be found in Vaxart's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vaxart Inc. Check Vaxart's Beneish M Score to see the likelihood of Vaxart's management manipulating its earnings.
Vaxart Workforce Analysis
Traditionally, organizations such as Vaxart use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Vaxart within its industry.Vaxart Manpower Efficiency
Return on Vaxart Manpower
| Revenue Per Employee | 273.3K | |
| Revenue Per Executive | 1.8M | |
| Net Loss Per Employee | 637.6K | |
| Net Loss Per Executive | 4.2M |
Additional Tools for Vaxart Stock Analysis
When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.